All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.
Bluebird bio $BLUE has unveiled its price for the newly approved gene therapy Zynteglo (LentiGlobin), which came as a big surprise. And it wasn't the only unexpected twist in today's ...
AstraZeneca and Merck’s PARP inhibitor Lynparza has carved itself a niche in Europe.
Five months after getting a speedy approval from the US regulator for frontline maintenance ...
If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS by John Carroll & team — all the news at 11:30a ET
EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET